Back to Results
First PageMeta Content
Growth factors / Hematology / Amgen / Cytokines / Granulocyte colony-stimulating factor / Filgrastim / Hospira / Pegfilgrastim / Reliance Life Sciences / Biology / Medicine / Pharmacology


Document Date: 2012-06-03 05:37:23

Open Document

File Size: 3,45 MB

Share Result on Facebook

Company

Biotech Forschungs GmbH / Takeda Pharmaceutical Company Limited / Reliance Life Sciences Pvt. Ltd. / Arzneimittel GmbH / Intas/Apotex Inc. / Sandoz GmbH / Biocon Ltd. / Sanofi-Aventis (Sanofi) ratiopharm GmbH / Hospira Inc. / Micromet Inc. / FILER AMGEN INC / Celgene Corporation / Merck & Company Inc. / Amgen Inc. / BioVex Group Inc. / BUSINESS Overview Amgen Inc. / DaVita Inc. / Kirin-Amgen Inc. / Laboratório Químico Farmacêutico Bérgamo Ltda / Teva Pharmaceutical Industries Ltd. / Kirin Holdings Company Limited / The NASDAQ Global Select Market Securities / Distribution Reimbursement Manufacturing / Teva Pharmaceutical Industries / /

Continent

Europe / /

Country

Puerto Rico / Netherlands / Brazil / Canada / Australia / Italy / New Zealand / United States / /

Currency

USD / /

Event

FDA Phase / Business Partnership / Dividend Issuance / M&A / Security Buyback / General or Shareholder Meeting / /

IndustryTerm

fewer products / biotechnology medicines / competing products / biological and pharmaceutical products / molecule products / bulk manufacturing / treatment of cancer / cancer care / prevention of infectious disease / clinical manufacturing facilities / clinical and manufacturing expertise / biosimilar products / manufacturing / large pharmaceutical corporations / healthcare providers / marketed products / filgrastim product / Biological products / treatment of metastatic colorectal cancer / biotechnology / patient convenience/delivery devices / reference product / biological product / treatment of malignant melanoma / reproducible commercial manufacturing processes / corporate Web site / pharmaceutical / healthcare provider communication plan / healthcare reform legislation / payer healthcare programs / biotechnology company developing treatments / biosimilar product / biosimilar applications / manufacturing operations / dialysis services / /

MedicalCondition

body fight infection / supportive cancer / chronic kidney disease / inflammatory diseases / tumor / congenital neutropenia / cancer / tumors / neutropenia / bone metastases / fever / malignant melanoma / diseases / infection / infectious disease / acute myeloid leukemia / related end stage renal disease / solid tumors / severe infection / febrile neutropenia / severe chronic neutropenia / chemotherapy-induced febrile neutropenia / cancers / neutropenia and neutropenia / advanced nonsquamous non small cell lung cancer / metastatic colorectal cancer / tumor necrosis factor / inflammation / cyclic neutropenia / /

MedicalTreatment

dialysis / chemotherapy / /

Organization

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington / D.C. / Administration of Neulasta / Medicare / European Commission / European Union / Securities and Exchange Commission / Internal Revenue Service / U.S. Food and Drug Administration / I.R.S. / /

/

Position

General / EXECUTIVE / driver / Hb / Territory U.S. U.S. General / DIRECTOR INDEPENDENCE PRINCIPAL ACCOUNTING FEES AND SERVICES EXHIBITS AND FINANCIAL STATEMENT SCHEDULES / / /

Product

Aranesp / NEUPOGEN / Neulasta / ESAs / Vectibix / Sensipar / Leukine / polyethylene glycol / Biologics / Enbrel / NEUPOGEN® / XGEVA® / Vectibix® / Aranesp® / Granocyte® / XM02 / Europe / XGEVA® (denosumab) / /

ProvinceOrState

Incorp / Delaware / /

Region

U.S. Europe / /

Technology

neuroscience / HTML / chemotherapy / dialysis / antibodies / biotechnology / ESA / transplantation / Drug development / /

URL

www.secdatabase.com / www.sec.gov / www.amgen.com / /

SocialTag